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Abstract
Background: Genome wide linkage scans have often been successful in the identification of
genetic regions containing susceptibility genes for a disease. Meta analysis is used to synthesize
information and can even deliver evidence for findings missed by original studies. If researchers are
not contributing their data, extracting valid information from publications is technically challenging,
but worth the effort. We propose an approach to include data extracted from published figures of
genome wide linkage scans. The validity of the extraction was examined on the basis of those 25
markers, for which sufficient information was reported. Monte Carlo simulations were used to take
into account the uncertainty in marker position and in linkage test statistic. For the final meta
analysis we compared the Genome Search Meta Analysis method (GSMA) and the Corrected p-
value Meta analysis Method (CPMM). An application to Parkinson's disease is given. Because we had
to use secondary data a meta analysis based on original summary values would be desirable.
Results: Data uncertainty by replicated extraction of marker position is shown to be much smaller
than 30 cM, a distance up to which a maximum LOD score may usually be found away from the
true locus. The main findings are not impaired by data uncertainty.
Conclusion: Applying the proposed method a novel linked region for Parkinson's disease was
identified on chromosome 14 (p = 0.036). Comparing the two meta analysis methods we found in
this analysis more regions of interest being identified by GSMA, whereas CPMM provides stronger
evidence for linkage. For further validation of the extraction method comparisons with raw data
would be required.
Background
Genome wide linkage scans have often been successful in
the identification of genes for monogenic diseases. How-
ever, the chance of success decreases by the multiplicity of
genetic and environmental determinants involved in the
aetiology of a complex disease. The contribution of each
disease gene to overall risk is presumed to be small, and
thus large sample sizes are required to detect the effect [1].
An ad hoc approach is to look for genomic regions that
obtain evidence for linkage across several scans, but this
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provides no direct statistical assessment. A statistically
more rigorous and powerful approach to pool results
would be a 'mega analysis' using original genotypes and
analyze these as a single dataset as suggested by Lander
and Kruglyak [2]. Pooling of samples across different
studies will increase the sample size and hence help to
find loci with small effects. However, one should expect
studies to vary in many respects, e.g. ascertainment criteria
(multiplex families, sib pair families, and a single large
multigenerational family), definition of phenotypes (e.g.
diagnostic scheme) and different marker data sets (Marsh-
field map, Genethon, Decode map). As these marker data
sets vary in marker spacing as well as in marker density
this leads to further heterogeneity. Moreover, variability
in the sample sizes across different studies leads to incon-
sistencies in the results. Besides that, different ways to
incorporate the possible covariates (which are rarely pub-
lished in detail) are methodological handicaps in a
pooled analysis. So, pooling of raw data across several
studies needs to be carried out and interpreted with cau-
tion. Even though some of these problems cannot be
overcome by a meta analysis, pooling of raw data is not
necessarily feasible[3].
As the raw genotype data might not always be available to
the public, more flexible approaches are required to carry
out the meta analysis. In this context Allison and Heo
used the Fisher method of combining the p-values across
candidate regions in a study of obesity [4]. Province sug-
gested a p-value of 0.72 (= 1/2ln(2)) [5] to overcome the
problem of setting all negative evidence against linkage to
zero in nonparametric linkage methods. Recently Badner
and Gershon [6] proposed an extended approach of com-
bining the p-values across different studies, further on
labelled as Corrected p-value Meta analysis Method
(CPMM). In CPMM, each reported p-value of a candidate
region needs to be transformed by an equation originally
given by Lander and Kruglyak [2]. Then, the minimum of
these transformed p-values is corrected for the size of the
candidate region. Finally Wise etal. [7,8] developed a
Genome Search Meta Analysis method (GSMA) specifi-
cally to carry out the meta analysis of genome wide link-
age searches. GSMA is a nonparametric method based on
rank statistics.
If researchers are reluctant to contribute even summary
measures like test statistics for linkage (LS), rest assured
one may introduce some bias into a meta analysis, similar
to publication bias. Additionally, the power of the meta
analysis will be decreased. Even if the meta analysis con-
tains an amount of uncertain summary data, the results
will provide a higher level of validity than by simply view-
ing the individual findings. Therefore they are highly val-
uable in deciding how to proceed next, e.g. which regions
to pursue in further studies. That said, one should con-
sider such approaches as preliminary, and the necessity to
discuss the impact of data uncertainty onto the findings
still remains.
In this study we propose a way to reconstruct test statistics
for linkage (LS) and corresponding marker positions as
the key summary measure of genome wide scans from
condensed materials such as figures in published papers.
Furthermore we carry out the meta analysis of all pub-
lished genome wide scans of susceptibility to PD taking
into account the uncertainty of the summary measures by
using the GSMA and CPMM.
In this investigation we demonstrate with using PD as an
example, how a meta analysis of genome wide linkage
searches can be carried out to data with uncertainty when
using data extraction. The influence of data uncertainty on
the results is discussed and differences between methods
are shown.
Results
By applying inclusion criteria, the meta analysis is based
on all published investigations for genome wide linkage
to PD as the phenotype of interest: Scottetal. [9], Pank-
ratzetal. [10], DeStefanoetal. [11], Martinezetal. [12] and
Hicksetal. [13]. We did not include the genome wide
scans by Hampshireetal[14] and Funayamaetal[15],
because patients included suffered from the Kufor-Rakeb-
syndrome or Parkinsonism, respectively.
Quality of extraction
With the methodology proposed above, we were able to
extract the same number of markers (n = 344) as origi-
nally investigated by Scottetal. [9]. From the paper by Pan-
kratzetal. [10], the positions and LS of 230 markers could
be estimated from figure 2, corresponding to 58% of 400
investigated markers. The corresponding numbers for fig-
ure 2 from Hicksetal. [13] are 426 markers (54% of 781
investigated markers), and those for figure 1 from Martin-
ezetal. [12] are 261 markers (67% of 391 investigated
markers). DeStefanoetal. [11] provided illustrations for
only 4 chromosomes, accounting for the reduced number
of extracted markers (12% of 399 investigated markers).
Positions and corresponding LSs of a total of 25 markers
were provided in the original papers. The extracted LSs
were almost similar to those reported (maximal deviation:
1.15 extracted, 1.24 reported in paper). For two markers
the extracted mean positions deviated from those
reported by ~12 cM and ~16 cM (corresponding report:
table 1,[10]). However, the extracted positions were only
4 cM and 9 cM apart from the sex-averaged locations given
by the Marshfield map [16].BMC Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2156/8/44
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Using our method of extraction, markers yielding higher
LS are unambiguously identified in a figure. Thus, we may
assume that missed markers are exclusively those with a
low value of the LS. Moreover, the estimated standard
error of LS ranges from approx. 0 to 0.07 LS-units. The
largest deviation was 0.29 LS-units. On average LS of a
marker was extracted within a range of 0.06 LS-units. This
precision is satisfactory for the coarse grid of genome wide
scans.
In order to take into account the uncertainty in marker
positions, the estimated standard errors of extracted posi-
tions for one marker ranges from approx. 0 to 4.15 cM.
The largest span between two single extractions is 28 cM.
Position uncertainty was exceptionally high on chromo-
some X, which was printed with an open ended axis in
two figures. Hence, locating markers on this chromosome
must be regarded as problematic.
CPMM
We found evidence for linkage on chromosomes 1 (p =
0.0074) and X (p = 0.0015). In a leave-one-(study-)out
cross-validation analysis we did not find any significant
linkage. This shows the heterogeneity of the scans,
because both findings are primarily caused by the results
of one single included genome scan each. The results
obtained by CPMM did not reach the level of genome
wide significance as suggested by the Lander and Kruglyak
criteria [2]. However, they showed a trend towards link-
age.
GSMA
The most significant results by the summed-rank-statistic
(SR) could be achieved for the 6th 30 cM bin on chromo-
some 9 (pSR = 0.0145). Furthermore, for the 6th 30 cM bin
on chromosome5 (pSR = 0.0363), for the 5th 30 cM bin on
chromosome 14 (pSR = 0.0363) and for the 4th 30 cM bin
on chromosome 1 (pSR = 0.0492) locally significant sig-
nals were achieved. The individual ranks for these regions
ranged from 51 to 118. Neither for heterogeneity nor for
homogeneity between studies evidence was given for any
bin (phet from 0.1550 to 0.3320). Adjacent to the signifi-
cant 6th bin, the 4th (pSR = 0.0874) and 5th bin (pSR =
0.0940) of chromosome 9 showed some trend towards
linkage. Similarly, adjacent to the significant 6th bin of
chromosome 5, the 5th bin (pSR = 0.0940) showed some
trend towards linkage. The summed-rank-statistics of each
30 cM bin are shown in figure 1.
The results of the weighted and the unweighted GSMA-
analysis were comparable. While the finding of the 6th bin
of chromosome 9 got slightly more significant for the
weighted-summed rank-statistic (SRweight) (pSR-weight  =
0.0120), the p-value for the 4th bin of chromosome 1
ascended above 5% (pSR-weight = 0.0546). In addition, for
the 1st bin of chromosome 17 the weighted GSMA-analy-
GSMA-results: summed-rank distribution of 30 cM bins Figure 1
GSMA-results: summed-rank distribution of 30 cM bins. boundary refers to the p-quantil of the distribution of summed ranks 
assuming no linkage
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sis provided a locally significant finding (pSR = 0.0752,
pSR-weight = 0.0460).
The p-values of the findings using 30 cM bins of chromo-
somes 5 and 9 changed slightly when using 60 cM bins,
but they did not fall below 0.00847 (suggestive genome
wide evidence). The 3rd60 cM bin of chromosome 5 (cor-
responding to the 5th and 6th 30 cM bin) achieved nomi-
nal significance by pSR = 0.0186 and pSR-weight = 0.01438.
The 3rd60 cM bin of chromosome 9 (corresponding to the
5th and 6th 30 cM bin) achieved a nominal significance of
pSR = 0.0353 and pSR-weight = 0.0238.
All these findings remained significant when accounting
for data uncertainty by simulation and achieved p-values
less than 0.05 in all 333 replications (table 2). No further
suggestive evidence for linkage (p < 0.05) can be seen in
any of the 333 replications.
Discussion
We applied data extraction combined with assessing data
uncertainty to carry out the meta analysis of genome wide
scans of linkage to PD from all published investigations.
If known studies without accessible data are not consid-
ered, a bias might be introduced in meta analysis so that
this problem is reduced by using as much information as
possible from published figures. To examine the validity
of the extraction method a comparison with all summary
measures from the considered genome wide scans would
naturally be desirable. Such precise information about LS
and the corresponding marker position was reported for
only 25 markers in the papers considered. Please note that
these markers are those relaying the most outstanding
information about linkage. For these markers, we found
the precision of the extraction, both for LS and position,
to be satisfactory for GSMA where information is pooled
within bins of 30 cM size. For the remaining markers, the
use of extracted LSs and positions is based on two assump-
tions: Firstly, missed markers are exclusively those with a
low LS. Secondly, a potentially greater uncertainty at
markers with lower LS does not have any decisive influ-
ence on the results of the meta analysis. This is reasonable,
since only the highest LS in each bin is used for GSMA.
Furthermore and since none of the bins with exclusively
low LS was even suggestively significant in none of the
MC-replications, these assumptions may be met. How-
ever, a further validation of the extraction method is
required. An adequate estimation of sensitivity and specif-
icity of the findings when applying the extraction method
can only be achieved by comparing with findings from a
pooled analysis of all raw data.
Both meta analysis methods considered here are robust
with respect to design, as they can deal with differences in
structure and number of families between studies, quanti-
tative and qualitative phenotype definition, genetic mark-
ers analysed and methods of statistical analysis. In
addition, no assumptions on the mode of inheritance or
genetic heterogeneity are necessary for the valid applica-
tion of these two methods. The distribution and interpre-
Table 1: Characteristics of whole genome scans for linkage for Parkinson's disease
Reference DeStefanoetal. [11] Scottetal[9] Hicksetal[13] Pankratzetal[10] Martinezetal[12]
Source Population US US Iceland US US + Europe
Diagnostic criteria UKPDS (adapted) 2 cardinal PD-signs + 
exclusion criteria
2 cardinal PD-signs + 
Hoen-Yahr crit.
UPDRS (II+III) Diagnosis 
Check List
3 cardinal PD-signs or 2 signs and 
at least 30% improvement with 
levodpoa treatment no parkin 
mutations
Family Structure ASP multiplex families multiplex families multiplex families multiplex families
No. of Families 113 174 51 325 (170ASP) 199 (227 ASP)
No. of Affected 226 378 117 192 471
No. of Marker 392 344 781 400 SNPs 391
Average distance 11 cM 10 cM 8.6 cM 10 cM
Analysis MLS/NPL MLOD Zlr MLS MLS
Significant region/markers 9 – D9S1825 5q–D5S816
8p–D8S520
17q – D17S921
1p32–D1S231
D1S2652
2 – D2S206 2p–D2S160
5q–D5S471
6q–D6S257
7p–D7S531
11q–D11S4175
2 – D2S206
19 q – D19S902
*signs compatible with common PD
1 France, United Kingdom, Netherlands, Germany and Italy
2 Weber set 8
3 ABI Prism Linkage Set
ASPaffected sib pair
∅ average
UKPDS UK Parkinson Disease Society Brain Bank Clinical Diagnosis Criteria
UPDRSUnified Parkinson Disease Rating Scale
MLS Maximum Likelihood Score
MLOD Maximum Parametric LOD Score
NPL Nonparametric Linkage Score
Zlr converted LOD score: v [2ln (10)LOD]BMC Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2156/8/44
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tation of the linkage test statistics does depend on the
statistical method applied. This is no problem for GSMA,
since test statistics are ranked within the single scans. The
key information used by CPMM is based on p-values,
which may be converted from test statistics for linkage by
a known relation. But CPMM requires the raw data to pro-
duce reliable results. That was one of the reasons for devel-
oping GSMA [17].
To our knowledge no extensive comparison between
these methods has been published yet. Thus the relative
power of these methods is not yet clear. While with GSMA
one searches for evidence for linkage across studies in pre-
specified genomic segments (termed as bins), CPMM
identifies regions of clustered markers with LS-values indi-
cating towards linkage and assessing significance using p-
values corrected for the size of the region. In the presence
of uncertainty in marker position it remains unclear
which of these approaches remains more powerful or
robust. Please note, that it could be problematic to com-
bine the lowest p-values from genome scans particularly
for smaller scans, because of a severe bias towards linkage
[18]. Giving for instant full weight to very low p-values,
CPMM could better detect linkage in the presence of sub-
stantial heterogeneity across samples. GSMA might be
more powerful when small genetic effects are present in
all samples. [17].
Data uncertainty in linkage statistics and marker positions
does not deteriorate the strength of the main findings.
Since markers are allocated into bins for GSMA, uncer-
tainty in position is reduced to uncertainty of allocation.
This allocation is ambiguous only for a small proportion
of markers, of which only a small proportion is important
for the ranking of bins. Consequently, one might expect
less variability in GSMA results due to uncertainty in posi-
tion. The direct comparison of extracted values of markers
to reported values, if available, shows the robustness of
the whole approach. The only notable differences
appeared from the deviation of original reported marker
position to those given by the Marshfield map. In sum-
mary, the extraction process led to tolerable uncertainty in
both position and test statistic for linkage.
In meta analysis it is important to consider departures
from homogeneity between the included studies. For
CPMM, the cross-validation as a test of heterogeneity
addresses whether the overall results are primarily affected
by one single scan. The test of heterogeneous ranks for a
bin might lack power when the number of scan is low. So
it does not come as a surprise that we were unable to find
evidence of either homogeneity or heterogeneity for any
of the major findings.
GSMA appears to be robust towards imprecise data
extracted from papers reporting genome wide scans. Set-
ting the analysis into a Monte-Carlo framework and com-
paring results to those of different meta-analytical
approaches is a possible way of investigating the sensitiv-
ity to uncertainty. However, GSMA and CPMM lead only
in parts to concurrent results, applying both methods to
our data collection. GSMA came up with more regions of
interest, whereas CPMM provided stronger evidence for
linkage by lower p-values. Lewis et al. [19] applied the
GSMA method to data of families of schizophrenia
patients and compared their results with those of a CPMM
approach of Badner and Gershon [20]. With GSMA it was
possible to identify more significant linkage regions than
Table 2: Summary of significant findings of GSMA and CPMM
chromosome GSMA CPMM
30 cM bin previous reports location SR analysis MC-Replications n (%) from 333* p-value for whole 
chromosome
pSR pSR-weight SR* Ranks* < 1% 1%–5% 5%–10%
13 th Hicks (LOD = 4.9) 58 – 87 cM 0.498 0.661 298 8 – 118 -- -- -- 0.007
4th 87 – 116 cM 0.050 0.055 430 51 – 117 -- 333 100% --
24 th Martinez (MLS = 2.0) 89 – 120 cM 0.220 0.147 358 39 – 115 -- -- -- 0.250
5th 120 – 149 cM 0.183 0.096 368 7 – 118 -- -- 8 2%
7th Pankratz (LOD = 2.5) 179 – 209 cM 0.447 0.427 308 51 – 73 -- -- --
55 th Hicks (LOD = 1.6) 113 – 141 cM 0.094 0.099 399 49 – 125 -- 18 5% 315 95% 0.108
6th Scott (MLOD = 2.4) 142 – 169 cM 0.036 0.034 506 51 – 118 -- 333 100% --
3rd-60 cM Martinez (MLS = 1.1) 132 – 198 cM 0.019 0.014 224.5 24.5 – 58 -- 304 91% 29 9%
81 st Scott (MLOD = 2.0) 0 – 28 cM 0.131 0.208 384.5 14.5 – 117 -- -- -- 0.331
96 th DeStefano (MLS = 1.3) 140 – 169 cM 0.015 0.012 461 55 – 114 -- 333 100% -- 0.321
3rd-60 cM 112 – 169 cM 0.035 0.238 215 16 – 58 -- 332 99% 1 <1%
14 5th 110 – 138 cM 0.036 0.047 434 51 – 115 -- 333 100% 0.300
X Pankratz (LOD = 2.5) ---- not in GSMA analysis --- 0.002
* for 30 cM bin analysis: SR ranges from 5 to 590, ranks are ranging from 1 to 118
for 60 cM bin analysis: SR ranges from 5 to 290, ranks are ranging from 1 to 58.
** Remaining replications show p ≥ 10%
Chromosomes 2 and 8 are listed, because findings therefore have been reported by individual scans.BMC Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2156/8/44
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with CPMM. However, this comparison is limited,
because different data sets were included into the meta
analyses. Subsequently, there is no evidence to generalise
this observation in the comparison of the two methods.
Finally, our approach is limited by the use of uncertain
secondary data instead of original summary statistics.
Hence, a meta analysis based on all real summary values
to verify these preliminary results would be desirable both
to further validate our approach and to give further sup-
port to the results regarding PD.
Linkage to PD
GSMA yields weak evidence for linkage to PD for 30 cM
bins on chromosomes 1, 5, 9 and 14. While evidence for
linkage on chromosome 1 was also provided by CPMM,
the findings for chromosomes 5 and 9 remain stable
when enlarging the size of the bin to 60 cM or weighting
studies according to their number of affected cases
included. Additional evidence for linkage was also
obtained on chromosome X by CPMM, not detected by
GSMA.
We are unable to find a genome wide significant or
genome wide suggestive evidence of linkage in our meta
analysis based on a total of 1384 affected individuals in
862 families.
The conspicuous 30 cM bin on chromosome 1 (87–116
cM) overlaps with the PARK10 region designated by Hicks
et al. [13]. This finding is tally to recently shown genome
wide significant associations of SNPs within the PARK10
region [21]. However, in our meta analysis we obtained a
linkage signal in this region only if the genome scan from
the isolated population in Iceland [13] was included. We
could not confirm the evidence of linkage when excluding
this most significant single result. Thus, even for the most
prominent result we found noticeable heterogeneity
among genome scans.
The finding on chromosome 5 (132–198 cM) was yet sus-
pected before [12] by viewing the results of the genome
wide scans. Four of these scans found evidence for linkage
within a 10 cM interval. Here we attach a p-value of 0.03
(using GSMA) to this result. This is supported by Maraga-
nore et al. [21], who found 2 of eleven associated SNPs
(all genome wide significant) located on chromosome 5.
The finding on chromosome 9 (112–169 cM) was high-
lighted by DeStefanoet al. [11] by a maximum lod score
of 1.3 at position 136 cM. This finding is supported by a
combination of weaker signals (LS between 0.7 and 1.16)
located up to 44 cM apart of two single genome scans
[10,12].
The linkage signal on chromosome 14 (110 – 138 cM)
arises from the combination of weak signals (LS between
0.62 and 1.6) located within a 9 cM distance of three sin-
gle genome scans [9,10,13].
Our meta analysis was performed on the basis of only five
independent studies. Thus one should regard this finding
as an add-in to the list of potential linkage regions.
The findings on chromosomes 9 and 14 supported the
results of a whole-genome association study carried out in
a sample of idiopathic PD-patients from an isolated pop-
ulation in the Netherlands, recently published by Bertoli-
Avella et al[22]. They found strong evidence for associa-
tion close to the markers D9S1838 (located at 163 cM)
and D14S65 (located at 108–129 cM).
Conclusion
The aetiology of a complex disease like PD is thought to
involve several genetic and environmental components
and is characterized by a comparatively low genetic herit-
ability. This complicates the search for new candidate
genes by genome wide linkage scans. Here, we showed a
methodology to extract information from published fig-
ures to overcome the bias of inaccessible data. We confirm
the evidence of linkage on chromosomes 1, 5 and X. Addi-
tionally a signal on chromosome 14 was also obtained
which needs confirming replication. With the availability
of ultra-high-volume genotyping platforms and 500 K
gene chips genome wide association studies should be
regarded as a promising addition to already performed
linkage scans [21,23,24].
Methods
Method of data extraction
Figures presenting test statistics for linkage (LS) were cop-
ied from the electronic versions of the original papers into
a Microsoft Word® document. We electronically enlarged
figures to size A4 in order to gauge crude LS and marker
positions on the chromosome, placing arrows from the
zero-point to a dot or vertex in the diagram. Length and
height values of the arrows were calibrated and rescaled
along measurements of the y-axis (linkage statistic) and
the chromosome limits plotted along the x-axis (posi-
tion). More accurate estimates of position could be
achieved by placing the arrows at the beginning of each
chromosome rather than at the zero-point of the x-axis.
Data extraction was accomplished nine times for each
study, each time blinded to previous extractions. In order
to take into account the uncertainty in position, extrac-
tions were matched, clustering the nearest points. The dis-
tance between two points i and j was calculated by
, with f as a factor to d f LS LS Pos Pos ij i j i j =− + − () ( ) 22BMC Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2156/8/44
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correct for different scales (LS-units vs. cM). It also can be
used to give higher weights to differences of LS than to
that of positions, since neighbouring points can be distin-
guished more easily by LS than by position. A value of f =
8 was empirically found useful showing no clear mis-
match.
The quality of data extraction was separately checked by
visual inspection for each extraction and for the mean of
extractions. Finally, the mean and the standard error of
matched extracted LS and positions were calculated and
used for the subsequent meta analysis. Standard errors for
markers extracted only once were defined as equal to the
median standard error of all remaining markers. We
directly used LS when LS and corresponding marker posi-
tions were reported in the articles. In this case standard
errors were set to zero.
Methods of meta analysis
CPMM
CPMM is based on p-values for linkage peaks. Badner and
Gershon [6] suggested that those nominal p-values per
locus have to be corrected for genome wide testing,
because evidence for linkage can occur in a region of up to
30 cM away from the disease susceptible locus[6]. They
refer to Feingold et al. [25], who estimated the probability
p* for the minimum p-value being observed within such
a linkage region.
This corrected p-value for such a region is,
where the notation is as follows: p denotes the Bonferroni
corrected point-wise p-value from each scan to take mul-
tiple testing into account. C denotes the number of chro-
mosomes. λ denotes the rate of crossovers per Morgan
given by Lander and Kruglyak [2]; it depends on the anal-
ysis method and family structure. G denotes the size of the
linkage region in Morgan, here G = 60 cM. Z (p) denotes
the standard normal inverse of p. φ[Z(p)] the density func-
tion of the normal distribution. Δ denotes the average
marker spacing in Morgan. ν (x) denotes the discreteness
correction for the distance between markers; for x <2 we
have v (x) ≈ exp (-0.583x).
This equation differs from that used by Badner and Gers-
hon[6] and given by Feingoldetal[25]. The first term pC
was replaced by 1- (1-p)C because observed p-values less
significant than 0.045 (LOD-scores of ~0.89) result in p*
> 1. Applying CPMM, we proceeded as follows: On each
chromosome the most significant marker, defined by the
maximum LS, was identified across all scans. A region ±
30 cM around this marker was considered a linkage region
if p* < 0.01. Hence, all LS of the remaining scans within a
linkage region were converted to p-values by using Hol-
man's triangle[26] as implemented in the Nyholt
table[27]. For the X chromosome we followed the X-
linked MLS approach as suggested by Cordell et al[28].
These p-values were further corrected yielding the corre-
sponding p*-values as described in the above equation.
The p-values of markers outside the linkage region were
set to 0.72 (= 1/2ln(2)) as suggested by Province [5].
For each region the multiple scan probability
 was calculated with
. n denotes the number
of scans considered, as originally suggested by RA. Fisher
in 1932[6].
According to the criteria for genome scans by Lander and
Kruglyak[2] we considered a linkage signal as suggestive
following application of CPMM when p = 0.0007 and as
significant when p = 0.00002. Cross-validation analysis
excluding the most significant result was carried out if
CPMM analysis yielded p ≤ 0.001[6].
GSMA
Briefly, the GSMA [7,8] method assesses evidence for link-
age by splitting all chromosomes into N bins of approxi-
mately equal size. For each genome scan included, the
most significant LS is recorded. Bins are then ranked in
order of significance with the most significant bin
assigned rank N. Equal test statistics for several bins
within a study were assigned tied ranks. The ranks of bins
are summed across the genome scans. This summed-rank-
statistic (SR) is compared to the critical values of a
summed-rank-distribution (Edgeworth series approxima-
tion[29]) under the null hypothesis of no linkage. We also
carried out a weighted GSMA analysis. For this each rank
was multiplied by its study weight ( ,
divided by the mean of this value of all studies) before
summed up to another summed-rank-statistic SRweight
[17].
For the analysis we did not consider the X chromosome.
The X chromosome was drawn on an open end scale in
some of the figures. Hence the position of the extracted
markers could only be determined rather impre-
cisely[14,15].
We considered an approximate bin size of 30 cM as rec-
ommended by Wiseetal[7]. In total 118 bins were used.
SR across all 5 studies ranged from 5 to 590.
pp G Z p Z p Z p C ∗ =− − + ⋅ ⋅ ⋅ 11 2 4 ( ) () [() ] [() ] λφ νλ Δ
MSP p p Y df :( ) , => −= χ α 11
22
Yp i f o r i t o n 2 21 =− ⋅ = ∗ ∑ log( )      
N affected cases ()  BMC Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2156/8/44
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For each bin we calculated p-values of three kinds of tests.
First, pSR  gives the probability of an arbitrary bin to
achieve the observed SR or a higher value. SR analysis
assesses the significance of each bin independently.
Applying Bonferroni correction for the number of bins,
significant genome wide evidence for linkage of 5%, as
defined by Lander and Kruglyak [2], will be equivalent to
pSR<0.00042 for 118 30 cM bins (expected once by chance
in 20 meta analyses). Suggestive evidence (expected once
by chance per single meta analysis) is given for a pSR <
0.00847.
Secondly, phet  gives the probability of heterogeneous
ranks across studies for a bin, conditional on the observed
rank sum. Therefore we used   as test
statistic, proposed by Zintzaras and Ioannidis[30,31],
where Rij is the rank of j-th bin in the i-th study and   is
the mean rank of the j-th bin across studies. A small phet
indicates consistent evidence for linkage across studies,
while a large phet indicates heterogeneity between the con-
sidered searches.
We assigned top ranks to known bins and the mean of the
remaining ranks to empty bins[7] to overcome the prob-
lem of missing values.
Sensitivity analysis
A Monte Carlo (MC) simulation approach[32] was used
to determine the change in SR due to data uncertainty for
LS and position caused by the extraction process. The sim-
ulations were replicated 333 times (replication number
limited by computer time) while randomly drawing a
marker position and LS from normal distributions, using
mean and standard error from data extraction.
The original studies forming the basis of this meta analysis
were all carried out in accordance with the Declaration of
Helsinki.
Literature selection of genome wide scans for Parkinson's 
disease
We carried out a literature search in MEDLINE for MESH-
headings Genetics, Parkinson's disease and genome scan
(or screening), restricted from 1998 to 2004 and sourced
references of neurological and genetic journals. In total we
were able to identify seven genome wide linkage scans of
Parkinson's disease [9-15]. Three family samples have
been reanalysed and published twice. Recently a genome
wide association of PD study was published, that we used
only for comparing results [21].
Inclusion/exclusion criteria for genome wide scan
The following criteria for the inclusion of genome wide
scans in the meta analysis were defined to ensure the qual-
ity of the individual studies and the data to be extracted:
1. Patients are included by status of Parkinson's disease
and not being selected e.g. by family history or therapy
response.
2. Statistical results are available in figures or tables for
whole chromosomes, at least for the major findings.
3. The statistical analysis is carried out by using estab-
lished genetic epidemiological methods.
4. The analysis concentrates exclusively on the susceptibil-
ity to PD, not e.g. to the age of onset. Thus the two
genome scans based on other phenotypes are excluded
[7].
The study characteristics of the five identified and
included genome wide scans on susceptibility to PD are
given in table 1.
Abbreviations
GSMA Genome Search Meta Analysis method
CPMM Corrected p-value Meta analysis Method
LS linkage statistic
SR summed-rank statistic
PD Parkinson's disease
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